STABLE SURFACE EXPRESSION OF INVARIANT CHAIN PREVENTS PEPTIDE PRESENTATION BY HLA-DR

被引:102
|
作者
ROCHE, PA
TELETSKI, CL
KARP, DR
PINET, V
BAKKE, O
LONG, EO
机构
[1] NIAID,IMMUNOGENET LAB,TWINBROOK II FACIL,12441 PARKLAWN DR,ROCKVILLE,MD 20852
[2] UNIV OSLO,DEPT BIOL,N-0316 OSLO,NORWAY
来源
EMBO JOURNAL | 1992年 / 11卷 / 08期
关键词
ANTIGEN PRESENTATION; ENDOSOME; HLA-DR; INTRACELLULAR TRAFFIC; INVARIANT CHAIN;
D O I
10.1002/j.1460-2075.1992.tb05351.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Class II major histocompatibility complex (MHC) molecules are cell surface glycoproteins that bind and present immunogenic peptides to T cells. Intracellularly, class II molecules associate with a polypeptide referred to as the invariant (Ii) chain. Ii is proteolytically degraded and dissociates from the class II complex prior to cell surface expression of the mature class II alpha-beta-heterodimer. Using human fibroblasts transfected with HLA-DR1 and Ii cDNAs, we now demonstrate that truncation of the cytoplasmic domain of Ii results in the failure of Ii to dissociate from the alpha-beta-Ii complex and leads to stable expression of class II alpha-beta-Ii complexes on the cell surface. Furthermore, biochemical analysis and peptide presentation assays demonstrated that transfectants with stable surface alpha-beta-Ii complexes expressed very few free alpha-beta heterodimers at the surface and were very inefficient in their ability to present immunogenic peptides to T cells. These results support the hypothesis that the cytoplasmic domain of Ii is responsible for endosomal targeting of alpha-beta-Ii and directly demonstrate that association with Ii interferes with the antigen presentation function of class II molecules.
引用
收藏
页码:2841 / 2847
页数:7
相关论文
共 50 条
  • [31] Regulatory effects of microRNAs on monocytic HLA-DR surface expression
    Folini, Anja
    Zhang, Lan
    Luedi, Markus M.
    Moolan-Vadackumchery, Robin
    Matthiss, Lena
    Hoffmann, Anneliese
    Stueber, Frank
    Huang, Melody Ying-Yu
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 (08)
  • [32] INVARIANT CHAIN PEPTIDES IN MOST HLA-DR MOLECULES OF AN ANTIGEN-PROCESSING MUTANT
    SETTE, A
    CEMAN, S
    KUBO, RT
    SAKAGUCHI, K
    APPELLA, E
    HUNT, DF
    DAVIS, TA
    MICHEL, H
    SHABANOWITZ, J
    RUDERSDORF, R
    GREY, HM
    DEMARS, R
    SCIENCE, 1992, 258 (5089) : 1801 - 1804
  • [33] HLA-DR expression and soluble HLA-DR levels in septic patients after trauma
    Ditschkowski, M
    Kreuzfelder, E
    Rebmann, V
    Ferencik, S
    Majetschak, M
    Schmid, EN
    Obertacke, U
    Hirche, H
    Schade, UF
    Grosse-Wilde, H
    ANNALS OF SURGERY, 1999, 229 (02) : 246 - 254
  • [34] DIFFERENTIAL EXPRESSION OF HLA-DR, HLA-DP, HLA-DQ AND ASSOCIATED INVARIANT CHAIN (II) IN NORMAL COLORECTAL MUCOSA, ADENOMA AND CARCINOMA
    DEGENER, T
    MOMBURG, F
    MOLLER, P
    VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1988, 412 (04) : 315 - 322
  • [35] HLA-DP, HLA-DQ, and HLA-DR Have Different Requirements for Invariant Chain and HLA-DM
    van Lith, Marcel
    McEwen-Smith, Rosanna M.
    Benham, Adam M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (52) : 40800 - 40808
  • [36] STRUCTURAL FEATURES OF THE INVARIANT CHAIN FRAGMENT CLIP CONTROLLING RAPID RELEASE FROM HLA-DR MOLECULES AND INHIBITION OF PEPTIDE BINDING
    KROPSHOFER, H
    VOGT, AB
    HAMMERLING, GJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (18) : 8313 - 8317
  • [38] ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY
    BOTTAZZO, GF
    PUJOLBORRELL, R
    HANAFUSA, T
    FELDMANN, M
    LANCET, 1983, 2 (8359): : 1115 - 1119
  • [39] A roadmap for HLA-DR peptide binding specificities
    Chelvanayagam, G
    HUMAN IMMUNOLOGY, 1997, 58 (02) : 61 - 69
  • [40] Decreased expression of HLA-DR antigen-associated invariant chain mRNA predicts mortality after septic shock
    M-A Cazalis
    L Cavé
    J Demaret
    V Barbalat
    E Cerrato
    A Lepape
    A Pachot
    G Monneret
    F Venet
    Critical Care, 16 (Suppl 3):